A Phase I, Open-Label, Dose Ranging Study to Assess the Safety and Distribution of Single or Multiple Doses of VB-111 in Patients With Advanced Metastatic Cancer.

Trial Profile

A Phase I, Open-Label, Dose Ranging Study to Assess the Safety and Distribution of Single or Multiple Doses of VB-111 in Patients With Advanced Metastatic Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs Ofranergene obadenovec (Primary)
  • Indications Neuroendocrine tumours; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors VBL Therapeutics
  • Most Recent Events

    • 26 Mar 2015 Planned End Date changed from 1 Sep 2014 to 1 Jun 2015 as per ClinicalTrials.gov record.
    • 26 Mar 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Jun 2015 as per ClinicalTrials.gov record.
    • 17 Feb 2015 Status changed from recruiting to completed, based on information in a VBL Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top